查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596729

他汀類藥物市場：按類型、藥物類別、應用、最終用戶分類 - 全球預測 2025-2030

Statins Market by Type (Natural Statins, Synthetic Statins), Drug Class (Atorvastatin, Fluvastatin, Lovastatin), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年他汀類藥物市場價值為316.1億美元，預計2024年將達到333億美元，複合年成長率為5.85%，預計2030年將達到470.8億美元。

他汀類藥物市場主要集中在抑制 HMG-CoA 還原酶的降膽固醇藥物，該酶對於肝臟中膽固醇的產生至關重要。這些藥物對於治療高血脂症非常重要，旨在降低心血管風險，進而解決全球心臟病發病率上升的問題。他汀類藥物市場的需求是由日益成長的公共衛生需求推動的，以控制心血管疾病，並廣泛應用於高膽固醇水平患者的一級和二級預防。最終用途包括醫院、診所和家庭配方，是市場消費的主要動力。人口老化、久坐的生活方式以及人們對控制膽固醇水平、推動成長的重要性的認知不斷提高，對市場動態產生了重大影響。此外，聯合治療和個人化醫療的出現正在為提高療效和患者依從性創造機會。專利到期後學名藥的激增也有望擴大市場准入。然而，副作用、藥物交互作用以及他汀類藥物以外的藥物（如 PCSK9 抑制劑）的存在等限制帶來了挑戰。嚴格的法規環境和新興替代療法的競爭進一步阻礙了市場成長，這些替代療法提供心血管益處且副作用更少。創新應著重於開發副作用最小的下一代他汀類藥物，並實施數位健康解決方案來追蹤患者的治療結果和依從性。另一個有前景的部分是生物技術的進步，可以更好地標靶化影響血脂水平的脂蛋白因子，這可能會帶來更好的治療結果。了解市場需要認知到向預防性護理的轉變以及消費者對心血管健康的日益成長的渴望，這正在推動公司利用創新的藥物和輸送系統。總之，儘管市場面臨挑戰，但策略創新和對監管環境的反應可以導致他汀類藥物領域的業務顯著成長。

主要市場統計
基準年[2023] 316.1億美元
預測年份 [2024] 333億美元
預測年份 [2030] 470.8億美元
複合年成長率（%） 5.85%

市場動態：揭示快速發展的他汀類藥物市場的關鍵市場洞察

他汀類藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球慢性病盛行率不斷上升
    • 消費者對非處方藥 (OTC) 的偏好日益成長
    • 由於消費者對保持健康生活方式的意識不斷增強，對他汀類藥物的需求增加
  • 市場限制因素
    • 新興國家對替代藥物的偏好日益成長
  • 市場機會
    • 開發新他汀類藥物的研發活動不斷成長
    • 對負擔得起且有效的膽固醇維持解決方案的需求不斷成長
  • 市場問題
    • 對他汀類藥物副作用的擔憂

波特五力：駕馭他汀類藥物市場的策略工具

波特的五力架構是了解他汀類藥物市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解他汀類藥物市場的外部影響

外部宏觀環境因素在塑造他汀類藥物市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解他汀類藥物市場的競爭格局

對他汀類藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：他汀類藥物市場供應商的績效評估

FPNV定位矩陣是評估他汀類藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製他汀類藥物市場的成功之路

對他汀類藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球慢性病發生率正在上升
      • 消費者對非處方藥 (OTC) 的偏好日益成長
      • 消費者保持健康生活方式意識的增強正在推動他汀類藥物的需求
    • 抑制因素
      • 新興國家對替代醫學的偏好日益成長
    • 機會
      • 擴大研發活動以開發新的他汀類藥物
      • 對負擔得起且有效的膽固醇維持解決方案的需求不斷成長
    • 任務
      • 對他汀類藥物副作用的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章他汀類藥物市場：依類型

  • 介紹
  • 天然他汀類藥物
  • 合成他汀類藥物

第7章 他汀類藥物市場：依藥物類別

  • 介紹
  • Atorvastatin
  • 氟伐他汀
  • 洛伐他汀
  • 匹伐他汀
  • rosuvastatin
  • Simvastatin

第8章他汀類藥物市場：依應用分類

  • 介紹
  • 發作
  • 心血管疾病
  • 糖尿病
  • 心臟病發作
  • 發炎
  • 文明病
  • 肥胖

第 9 章 他汀類藥物市場：依最終使用者分類

  • 介紹
  • 診所
  • 醫院

第10章 美洲他汀類藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太他汀類藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲他汀類藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Becton, Dickinson and Company
  • Biocon Limited
  • bioMerieux SA
  • Centrient Pharmaceuticals Netherlands BV
  • Concord BIoTech Limited
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffman-La Roche AG
  • GlaxoSmithKline PLC
  • Grifols, SA
  • Merck & Co., Inc.
  • Nova Biomedical
  • Novartis AG
  • Pfizer Inc.
  • Quidel Corporation
  • Siemens AG
  • Terumo Corporation
  • Thermo Fisher Scientific, Inc.
  • Trinity BIoTech PLC
Product Code: MRR-FF012EDC38C1

The Statins Market was valued at USD 31.61 billion in 2023, expected to reach USD 33.30 billion in 2024, and is projected to grow at a CAGR of 5.85%, to USD 47.08 billion by 2030.

The statin market focuses primarily on cholesterol-lowering medications that impede the enzyme HMG-CoA reductase, pivotal in cholesterol production within the liver. These drugs are critical in treating hyperlipidemia, aiming at cardiovascular risk reduction, thereby addressing soaring global heart disease rates. The statin market's necessity stems from the growing public health demand to manage cardiovascular diseases, with broad applications in both primary and secondary prevention for patients exhibiting high cholesterol levels. End-use spans hospital settings, clinics, and household prescriptions, fueling significant market consumption. Market dynamics are heavily influenced by an aging population, sedentary lifestyles, and increasing awareness of the importance of managing cholesterol levels, driving growth. Additionally, opportunities are emerging from the advent of combination therapies and personalized medicine, which could enhance efficacy and patient adherence. A surge in generic drugs post-patent expiration is also expected to expand market accessibility. However, limitations such as adverse side effects, drug interactions, and the presence of non-statins like PCSK9 inhibitors pose challenges. Market growth is further impeded by stringent regulatory environments and competition from emerging alternative treatments that promise cardiovascular benefits with fewer side effects. For innovation, focus should be on developing next-generation statins with minimal side effects and incorporating digital health solutions to track patient outcomes and adherence. Other promising areas include biotechnological advancements allowing for more refined targeting of lipoprotein factors influencing blood lipid levels, potentially achieving superior therapeutic outcomes. Understanding the marketplace entails recognizing a shift towards preventative healthcare measures and growing consumer inclination for thorough cardiovascular health, presenting businesses with opportunities to harness innovative drugs and delivery systems. Conclusively, while the market faces challenges, strategic innovation and responsiveness to regulatory landscapes can yield considerable business growth in the statin domain.

KEY MARKET STATISTICS
Base Year [2023] USD 31.61 billion
Estimated Year [2024] USD 33.30 billion
Forecast Year [2030] USD 47.08 billion
CAGR (%) 5.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Statins Market

The Statins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the incidence of chronic diseases globally
    • Rising consumer preference for over-the-counter (OTC) drugs
    • Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
  • Market Restraints
    • Increasing preference for alternative medicines in emerging economies
  • Market Opportunities
    • Growth in R&D activities for newer statin development
    • Emerging demand for affordable and effective cholesterol-maintaining solutions
  • Market Challenges
    • Concerns associated with side-effects of statins

Porter's Five Forces: A Strategic Tool for Navigating the Statins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Statins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Statins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Statins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Statins Market

A detailed market share analysis in the Statins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Statins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Statins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Statins Market

A strategic analysis of the Statins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Statins Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Ltd., Becton, Dickinson and Company, Biocon Limited, bioMerieux S.A., Centrient Pharmaceuticals Netherlands B.V., Concord Biotech Limited, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche AG, GlaxoSmithKline PLC, Grifols, S.A., Merck & Co., Inc., Nova Biomedical, Novartis AG, Pfizer Inc., Quidel Corporation, Siemens AG, Terumo Corporation, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Statins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Natural Statins and Synthetic Statins.
  • Based on Drug Class, market is studied across Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Rosuvastatin, and Simvastatin.
  • Based on Application, market is studied across Attacks, Cardiovascular Diseases, Diabetes, Heart Strokes, Inflammation, Lifestyle Diseases, and Obesity.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the incidence of chronic diseases globally
      • 5.1.1.2. Rising consumer preference for over-the-counter (OTC) drugs
      • 5.1.1.3. Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing preference for alternative medicines in emerging economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth in R&D activities for newer statin development
      • 5.1.3.2. Emerging demand for affordable and effective cholesterol-maintaining solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side-effects of statins
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Statins Market, by Type

  • 6.1. Introduction
  • 6.2. Natural Statins
  • 6.3. Synthetic Statins

7. Statins Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Atorvastatin
  • 7.3. Fluvastatin
  • 7.4. Lovastatin
  • 7.5. Pitavastatin
  • 7.6. Rosuvastatin
  • 7.7. Simvastatin

8. Statins Market, by Application

  • 8.1. Introduction
  • 8.2. Attacks
  • 8.3. Cardiovascular Diseases
  • 8.4. Diabetes
  • 8.5. Heart Strokes
  • 8.6. Inflammation
  • 8.7. Lifestyle Diseases
  • 8.8. Obesity

9. Statins Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals

10. Americas Statins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Statins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Statins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Ltd.
  • 6. Becton, Dickinson and Company
  • 7. Biocon Limited
  • 8. bioMerieux S.A.
  • 9. Centrient Pharmaceuticals Netherlands B.V.
  • 10. Concord Biotech Limited
  • 11. Danaher Corporation
  • 12. DiaSorin S.p.A.
  • 13. F. Hoffman-La Roche AG
  • 14. GlaxoSmithKline PLC
  • 15. Grifols, S.A.
  • 16. Merck & Co., Inc.
  • 17. Nova Biomedical
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Quidel Corporation
  • 21. Siemens AG
  • 22. Terumo Corporation
  • 23. Thermo Fisher Scientific, Inc.
  • 24. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. STATINS MARKET RESEARCH PROCESS
  • FIGURE 2. STATINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STATINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STATINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STATINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STATINS MARKET DYNAMICS
  • TABLE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STATINS MARKET SIZE, BY NATURAL STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STATINS MARKET SIZE, BY SYNTHETIC STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STATINS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STATINS MARKET SIZE, BY FLUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STATINS MARKET SIZE, BY LOVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STATINS MARKET SIZE, BY PITAVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STATINS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STATINS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STATINS MARKET SIZE, BY ATTACKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STATINS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STATINS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STATINS MARKET SIZE, BY HEART STROKES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STATINS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STATINS MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STATINS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STATINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STATINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STATINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. STATINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. STATINS MARKET, FPNV POSITIONING MATRIX, 2023